 Millendo Therapeutics NASDAQ:MLND was downgraded by Zacks Investment Research from a buy rating to a hold rating in a research note issued on Tuesday, Zacks.com reports. According to Zacks, Millendo Therapeutics Inc. is a biopharmaceutical company. It focuses on developing novel treatments for orphan endocrine diseases. The companys product candidate consists of AZP-531 and ATR-101 ... 